Poly-L-lactic acid (PLLA) was approved for use in Europe in 1999. In the United States, it was approved by the Food and Drug Administration in 2004 for the treatment of facial lipoatrophy associated with human immunodeficiency virus, and in 2009 for cosm
Important lessons have been learned in the use of injectable PLLA that have helped reduce the frequency of adverse events and make it desirable for restoring facial volume (Table 1). The importance of diffuse distribution of the injectable PLLA suspension
At week 24, mean improvement in WSRS from baseline was 2.09 0.68 for the PLA side and 1.54 0.65 for the HA side. Both injections were well toler- ated, and the adverse reactions were mild and transient in most cases. PLA provides noninferior efficac
